CXCR4 and colon carcinoma: These molecules were co-delivered into murine colon carcinoma cells MC-38 using chemokine receptor type 4 (CXCR4)-targeted polymeric NPs coated with poly-L-glutamic acid and a CXCR-4 antagonist peptide, mediating better binding with chemokine receptors, enhanced cytotoxicity and drug release, as well as content stability.